Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2022-11-30 Report Publication Anno…
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Advicenne annonce son calendrier financier 2023" (Advicenne announces its 2023 financial calendar). It explicitly lists future dates for key corporate events: Publication of 2022 annual results, Annual General Meeting (AGM), and Publication of 2023 half-year results. This document is an announcement about the schedule of future corporate reports and meetings, not the reports themselves. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement detailing the publication timing of other reports strongly suggests a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for announcing report publication schedules.
2022-11-30 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Advicenne dated November 3, 2022, announcing its participation in two upcoming international investor conferences (Jefferies London Healthcare Conference and J.P. Morgan HealthCare Conference). This type of announcement, which informs investors about future meetings and roadshows, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general communication aimed at investors regarding corporate activities. Since the document is short (under 5,000 characters) and serves primarily to announce future engagement with investors rather than releasing core financial results (ER), management analysis (MDA), or a formal report (10-K/IR), it fits best under the category of Investor Presentation (IP) as it is preparatory material for investor engagement, or potentially a Regulatory Filing (RNS) if it were purely administrative. Given the content focuses entirely on upcoming investor meetings and business development discussions, 'Investor Presentation' (IP) is the most specific fit among the options for proactive investor communication, although 'RNS' is a possibility if it were a mandatory regulatory disclosure. However, announcements about conference attendance are often grouped with investor relations materials. Since there is no specific category for 'Conference Attendance Announcement', and it is not a formal report, I will lean towards 'IP' as it directly relates to investor engagement strategy, or 'RNS' as a general regulatory/corporate update. Given the context of financial databases, announcements about investor outreach are often categorized under IP or RNS. I will select RNS as the safest general corporate announcement/regulatory filing fallback for this type of forward-looking corporate activity announcement that isn't a core financial report or management discussion.
2022-11-03 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release dated November 3, 2022, announcing the company's upcoming participation in two major international investor conferences (Jefferies London Healthcare Conference and J.P. Morgan Health Care Conference). This type of announcement, which informs investors about management's schedule for meetings and presentations at industry events, is best classified as an Investor Presentation (IP) related activity or, more broadly, a general corporate update. Since there is no specific category for 'Investor Conference Schedule Announcement,' and it is not a formal regulatory filing like 10-K, ER, or IR, it falls under the general category of investor relations communication. Given the options, 'Investor Presentation' (IP) is the closest fit as it relates directly to management engaging with investors, although it is an announcement *about* future presentations rather than the presentation itself. However, looking closely at the definitions, none perfectly capture a simple conference attendance announcement. It is not a Call Transcript (CT), Earnings Release (ER), or a formal report (10-K, IR). It is a corporate communication aimed at investors. If we must choose from the provided list, 'Investor Presentation' (IP) is the most contextually relevant category for management proactively communicating with the investment community about future engagement opportunities. Alternatively, 'Regulatory Filings' (RNS) is a fallback, but IP is more specific to the content's purpose.
2022-11-03 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific corporate event: the extension of intellectual property (patent protection) for the drug Sibnayal® via Supplementary Protection Certificates (SPCs) in European countries. This type of announcement, which details changes to intellectual property rights, often falls under general corporate updates or regulatory/legal matters. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a capital event (CAP). Since it concerns the legal protection of a core asset (IP), it is most closely related to legal proceedings or general regulatory announcements. Given the options, it is a specific corporate update that doesn't fit the primary financial or governance categories. It is not a transaction in own shares (POS) or a director's dealing (DIRS). It is not a proxy statement (PSI) or an AGM material (AGM-R). Since it is a specific announcement about a legal/regulatory asset protection, and not a general regulatory filing fallback (RNS), the closest fit among the specific categories is difficult. However, announcements regarding legal matters or significant corporate actions that aren't strictly financial or governance often default to the most general regulatory category if a more specific one isn't available. Since the core topic is the extension of IP rights, which is a legal/regulatory matter, and it is not a standard financial report, the most appropriate classification among the provided list, given the lack of a specific 'Intellectual Property Update' code, is the general Regulatory Filings (RNS) as a catch-all for specific, non-financial, non-governance announcements, or potentially LTR if the IP extension is viewed as a legal outcome. Given the positive nature (extension granted) and focus on asset protection rather than litigation, RNS is the safer general regulatory classification.
2022-10-05 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release from Advicenne dated October 5, 2022, announcing the extension of intellectual property protection (patent term extension via Supplementary Protection Certificates - SPCs) for its drug Sibnayal® until 2036 in several European countries. This type of announcement, concerning patents, intellectual property rights, and regulatory exclusivity for a product, is most closely related to the core assets and future commercial viability of the company. While it touches upon IP, it is not a formal legal filing (LTR) or a general regulatory announcement (RNS). It is a specific update on the company's core asset protection. Given the provided categories, this announcement about the extension of patent rights and associated manufacturing know-how is best classified as an update related to the company's core business and assets, which often falls under general Investor Relations material. Since there is no specific 'Intellectual Property Update' category, and it is not a financial report (ER, IR, 10-K), management change (MANG), or financing event (CAP), it is a significant corporate announcement. In the context of specialized financial filings, announcements regarding core product protection and exclusivity are often grouped with Investor Presentations (IP) or treated as a general Regulatory Filing (RNS) if no better fit exists. However, since it is a specific announcement about a key asset's protection, and not a presentation, RNS is the most appropriate fallback for a non-financial, non-management, non-legal proceeding corporate update that doesn't fit the other specific codes. It is a corporate news release.
2022-10-05 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "Advicenne reports its First Half Financial results as of June 30, 2022" and contains key financial highlights, a detailed table of financial data for H1 2022 vs H1 2021, management commentary on the results, and notes that the full report is available on the company website. The content focuses on summarizing the financial performance for a period shorter than a year (semi-annual results). This strongly indicates an Interim/Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it merely an announcement of a report's publication (RPA), as it contains substantial financial details. It is also not a Call Transcript (CT) or a formal Earnings Release (ER) which usually contains only the highest-level summary. H2 2022
2022-09-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.